Page 19 - Morphosys This News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys this. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys This Today - Breaking & Trending Today

MorphoSys AG: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost ....

United States , Dennis Riedl , Thomas Biegi , Julia Neugebauer , Eamonn Nolan , Jean Paul Kress , Morphosys Agview , Exchange Commission , Chief Executive Officer , Morphosy Annual Report , Investor Relations ,

'Challenging Market' Leads MorphoSys to Cut Preclinical R&D, Turn Focus to Cancer

MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck. ....

United Kingdom , Jean Paul Kress , Constellation Pharmaceuticals , Germany Based Morphosys , Massachusetts Based Constellation Pharmaceuticals , Paul Kress , Sierra Oncology , Imago Biosciences , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery ,

MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

United States , San Francisco , Thomas Biegi , Julia Neugebauer , Eamonn Nolan , Jean Paul Kress , Exchange Commission , Constellation Pharmaceuticals Inc , Paul Kress , Chief Executive Officer , Healthcare Conference , Standard Time , Morphosy Annual Report , Investor Relations , United States Wire Group ,

MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial ....

United States , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Morphosys Agview , Exchange Commission , Us Communications , Xencor Inc , Drug Administration , Financial Liabilities , Chief Executive Officer , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Investor Relations ,

MorphoSys CFO Sung Lee To Step Down In March 2023

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) said that its Chief Financial Officer and Management Board member, Sung Lee, has decided to leave the company to move back to California for personal ....

United States , Chief Financial Officer , Management Board , Sung Lee ,